{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:06:04Z","timestamp":1756382764697},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00105-018-4186-6","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T12:56:15Z","timestamp":1531227375000},"page":"11-13","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sarkoidose getriggert durch Immuncheckpoint-Blockade"],"prefix":"10.1007","volume":"69","author":[{"given":"Markus","family":"Heppt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Charlotte","family":"Niesert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Flaig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"4186_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1164\/rccm.201401-0188OC","volume":"190","author":"NA Braun","year":"2014","unstructured":"Braun NA, Celada LJ, Herazo-Maya JD et al (2014) Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T\u2011cell proliferative capacity. Am J Respir Crit Care Med 190:560\u2013571","journal-title":"Am J Respir Crit Care Med"},{"key":"4186_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000161122","volume":"218","author":"A Eckert","year":"2009","unstructured":"Eckert A, Schoeffler A, Dalle S et al (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a\u00a0metastatic melanoma patient. Dermatology 218:69\u201370","journal-title":"Dermatology"},{"key":"4186_CR3","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1097\/CJI.0b013e3181eef779","volume":"33","author":"LM Heinzerling","year":"2010","unstructured":"Heinzerling LM, Anliker MD, Muller J et al (2010) Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J\u00a0Immunother 33:834\u2013839","journal-title":"J Immunother"},{"key":"4186_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000362614","volume":"37","author":"KP Murphy","year":"2014","unstructured":"Murphy KP, Kennedy MP, Barry JE et al (2014) New-onset mediastinal and central nervous system sarcoidosis in a\u00a0patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 37:351\u2013353","journal-title":"Oncol Res Treat"},{"key":"4186_CR5","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1016\/j.jaad.2013.07.028","volume":"69","author":"RB Reule","year":"2013","unstructured":"Reule RB, North JP (2013) Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J\u00a0Am Acad Dermatol 69:e272\u2013e273","journal-title":"J Am Acad Dermatol"},{"key":"4186_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM et\u00a0al (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a\u00a0case report & review of the literature. J\u00a0Immunother Cancer 4:94","journal-title":"J Immunother Cancer"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4186-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4186-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T23:15:44Z","timestamp":1562714144000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4186-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":6,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4186"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4186-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"10 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Heppt erhielt Vortragshonorare und\/oder Beratungshonorare und\/oder Reiseunterst\u00fctzung von Novartis, Roche, BMS und MSD. C.\u00a0Berking erhielt Vortragshonorare und\/oder Beratungshonorare und\/oder Reiseunterst\u00fctzung von Amgen, AstraZeneca, BMS, Merck, MSD, Novartis, Pierre Fabre, Regeneron, Roche, und Sanofi-Aventis. A.\u2011C.\u00a0Niesert und M.\u00a0Flaig geben an, dass kein Interessenskonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This article is part of a\u00a0supplement sponsored by LEO Pharma GmbH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}